- Home
- DD vs INSM Comparison
DD vs INSM Comparison
Compare DD & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DD | INSM |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 23.0B |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DD | INSM |
|---|---|---|
| Price | $46.86 | $94.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $56.67 | ★ $201.17 |
| AVG Volume (30 Days) | 2.8M | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $20,397,000,000.00 | N/A |
| Revenue This Year | $6.72 | $182.31 |
| Revenue Next Year | $3.83 | $65.19 |
| P/E Ratio | $122.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.34 | $70.57 |
| 52 Week High | $83.40 | $212.75 |
Technical Indicators
Market Signals| Indicator | DD | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 27.16 |
| Support Level | $46.09 | N/A |
| Resistance Level | $48.15 | $166.81 |
| Average True Range (ATR) | 1.32 | 4.32 |
| MACD | -0.21 | 0.21 |
| Stochastic Oscillator | 15.63 | 4.96 |
Price Performance
Historical ComparisonAbout DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.